electroCore
Market Cap
US$55.9m
Last Updated
2019/10/16 00:44 UTC
Data Sources
Company Financials +
Executive Summary
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields.
Snowflake
Fundamentals
Adequate balance sheet and fair value.
Similar Companies
Share Price & News
How has electroCore's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-27.9%
ECOR
3.2%
US Medical Equipment
3.4%
US Market
1 Year Return
-84.7%
ECOR
10.0%
US Medical Equipment
5.4%
US Market
Return vs Industry: ECOR underperformed the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: ECOR underperformed the US Market which returned 5.4% over the past year.
Shareholder returns
| ECOR | Industry | Market | |
|---|---|---|---|
| 7 Day | -27.9% | 3.2% | 3.4% |
| 30 Day | -51.4% | -1.8% | -1.0% |
| 90 Day | 45.4% | -0.4% | -0.4% |
| 1 Year | -84.7%-84.7% | 10.9%10.0% | 7.7%5.4% |
| 3 Year | n/a | 69.9%64.8% | 46.2%36.8% |
| 5 Year | n/a | 128.2%102.9% | 65.6%47.5% |
Price Volatility Vs. Market
How volatile is electroCore's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Some electroCore (NASDAQ:ECOR) Shareholders Have Taken A Painful 84% Share Price Drop3 weeks ago | Simply Wall St
Will electroCore (NASDAQ:ECOR) Spend Its Cash Wisely?1 month ago | Simply Wall St
Director James L. Tullis Just Bought Shares In electroCore, Inc. (NASDAQ:ECOR)Valuation
Is electroCore undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: ECOR ($1.89) is trading below our estimate of fair value ($148.75)
Significantly Undervalued: ECOR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ECOR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: ECOR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate ECOR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ECOR is good value based on its PB Ratio (1.4x) compared to the US Medical Equipment industry average (3.6x).
Next Steps
Future Growth
How is electroCore forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
44.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ECOR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ECOR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ECOR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ECOR's revenue (59% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: ECOR's revenue (59% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if ECOR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has electroCore performed over the past 5 years?
-784.4%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: ECOR is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.
Accelerating Growth: Unable to compare ECOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECOR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: ECOR has a negative Return on Equity (-130.53%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: ECOR is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: ECOR is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is electroCore's financial position?
Financial Position Analysis
Short Term Liabilities: ECOR's short term assets ($47.2M) exceeds its short term liabilities ($7.1M)
Long Term Liabilities: ECOR's short term assets (47.2M) exceeds its long term liabilities (1.7M)
Debt to Equity History and Analysis
Debt Level: ECOR is debt free.
Reducing Debt: ECOR had no debt 5 years ago.
Balance Sheet
Inventory Level: ECOR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ECOR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECOR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ECOR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is electroCore's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate ECOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ECOR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if ECOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ECOR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ECOR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of electroCore's salary, the management and board of directors tenure and is there insider trading?
0.7yrs
Average management tenure
CEO
Dan Goldberger (60yo)
0yrs
Tenure
Mr. Daniel S. Goldberger, also known as Dan, has been Chief Executive Officer and Director at electroCore, Inc. since October 1, 2019. Mr. Goldberger served as Executive Chairman at Repro Med Systems, Inc. ...
Management Age and Tenure
0.7yrs
Average Tenure
55yo
Average Age
Experienced Management: ECOR's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Age and Tenure
3.7yrs
Average Tenure
61yo
Average Age
Experienced Board: ECOR's board of directors are considered experienced (3.7 years average tenure).
Insider Trading
Insider Buying: ECOR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 18,974 |
| Max Price | US$1.62 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 47,613 |
| Max Price | US$1.64 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 7,000 |
| Max Price | US$1.77 |
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman of the Board |
| Shares | 10,000 |
| Max Price | US$1.82 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Corporate Secretary |
| Shares | 10,000 |
| Max Price | US$1.72 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 21,000 |
| Max Price | US$1.82 |
| Entity | Individual |
| Role | Consultant Senior Executive Advisor of Medical & Government Affairs |
| Shares | 10,000 |
| Max Price | US$4.83 |
| Entity | Individual |
| Shares | 7,500 |
| Max Price | US$6.53 |
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman of the Board |
| Shares | 7,300 |
| Max Price | US$6.79 |
Ownership Breakdown
Management Team
Dan Goldberger (60yo)
CEO & Director
- Tenure: 0yrs
Joseph Errico (50yo)
Co-Founder
- Tenure: 14.8yrs
- Compensation: US$1.13m
Brian Posner (57yo)
CFO & Corporate Secretary
- Tenure: 0.5yrs
Peter Staats (55yo)
Senior Executive Advisor of Medical & Government Affairs
- Tenure: 0.6yrs
- Compensation: US$723.73k
Eric Liebler (55yo)
Senior Vice President of Neurology
- Tenure: 6.8yrs
Tony Fiorino (52yo)
Chief Medical Officer
- Tenure: 0.6yrs
Mike Romaniw (62yo)
Vice President of Operations
- Tenure: 0.8yrs
Board Members
Trevor Moody (54yo)
Independent Director
- Tenure: 6.6yrs
- Compensation: US$223.73k
Dan Goldberger (60yo)
CEO & Director
- Tenure: 0yrs
Carrie Cox (61yo)
Independent Chairman of the Board
- Tenure: 1.3yrs
- Compensation: US$235.86k
MIke Atieh (65yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: US$229.53k
Jim Tullis (72yo)
Independent Director
- Tenure: 5.3yrs
- Compensation: US$225.32k
Thomas Errico (67yo)
Independent Director
- Tenure: 14.1yrs
- Compensation: US$227.69k
Joseph Errico (50yo)
Co-Founder
- Tenure: 14.8yrs
- Compensation: US$1.13m
Nick Colucci (59yo)
Independent Director
- Tenure: 2.2yrs
- Compensation: US$228.35k
Stephen Ondra (62yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: US$223.07k
Company Information
electroCore, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: electroCore, Inc.
- Ticker: ECOR
- Exchange: NasdaqGS
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$55.932m
- Shares outstanding: 29.59m
- Website: https://www.electrocore.com
Number of Employees
Location
- electroCore, Inc.
- 150 Allen Road
- Suite 201
- Basking Ridge
- New Jersey
- 7920
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ECOR | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2018 |
| 43E | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2018 |
Biography
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in ne ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/16 00:44 |
| End of Day Share Price | 2019/10/15 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.